- |||||||||| Clinical, Journal: Clinical, Methodological, and Practical Considerations for Algorithmic Testing in Autoimmune Serology. (Pubmed Central) - Jan 29, 2022
Serology reflex testing algorithms for the evaluation of autoimmune diseases can support clinical diagnosis and laboratory resource use but may be challenging to implement and are often applied variably across institutions. Assessments of evidence-driven guidelines, clinical impact, and impact on laboratory workflow are essential to this task.
- |||||||||| Clinical, Journal: Disease severity and response to treatment in Iranian patients with myasthenia gravis. (Pubmed Central) - Jan 28, 2022
The overall outcome was favorable in the majority of patients, despite differences in the disease course and severity. In contrary to the previous reports, anti-MuSK positive patients in our series did not need a more vigorous treatment regimen comparing other serologic subtypes of MG.
- |||||||||| Journal: First characterization of congenital myasthenic syndrome type 5 in North Africa. (Pubmed Central) - Jan 28, 2022
COLQ mutations are probably underdiagnosed in these North African populations, this is an issue as CMS-5 may be treated with ephedrine, and albuterol. Indeed, patients can seriously benefit and even recover after the treatment that should be planned according to genetic tests and clinical findings.
- |||||||||| Biomarker, Journal: Competitive endogenous RNA network and pathway-based analysis of LncRNA single-nucleotide polymorphism in myasthenia gravis. (Pubmed Central) - Jan 28, 2022
Finally, functional analyses demonstrated lncRNA-SNPs mediated ceRNA regulation pairs associated with MG participated in the MAPK signaling pathway. In summary, we constructed MG-specific lncRNA-SNPs mediated ceRNA regulatory networks based on pathway in the present study, which was helpful to elucidate the roles of lncRNA-SNPs in the pathogenesis of MG and provide novel insights into mechanism of lncRNA-SNPs as potential genetic risk biomarkers of MG.
- |||||||||| Zilbrysq (zilucoplan) / UCB
Trial completion: RAISE: Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) - Jan 28, 2022 P3, N=174, Completed, In summary, we constructed MG-specific lncRNA-SNPs mediated ceRNA regulatory networks based on pathway in the present study, which was helpful to elucidate the roles of lncRNA-SNPs in the pathogenesis of MG and provide novel insights into mechanism of lncRNA-SNPs as potential genetic risk biomarkers of MG. Active, not recruiting --> Completed
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
UPFRONT IMMUNOMODULATORY TREATMENT OF IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS (Special Topics Moderated Poster Theater 5_Hall C) - Jan 28, 2022 - Abstract #ACC2022ACC_7070; The use of a UIM protocol in addition to steroids shows promise of decreased MACE without an increased risk of sepsis. Given the small number of patients treated with UIM, further studies are needed to better define the efficacy of the UIM protocol.
- |||||||||| Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen
A CASE OF MYOCARDITIS AND MYOSITIS FOLLOWING COVID19 VACCINE (eAbstract site) - Jan 28, 2022 - Abstract #ACC2022ACC_6730; Myocarditis in our patient may be related to either COVID infection or vaccine. Etiology of his acute on chronic myopathy from mitochondrial dysfunction is curious since COVID is also known to impact mitochondrial function.
- |||||||||| MYASTHENIA GRAVIS ASSOCIATED MYOCARDITIS SUCCESSFULLY TREATED WITH EMPIRIC IMMUNOSUPPRESSION (Poster Hall_Hall C) - Jan 28, 2022 - Abstract #ACC2022ACC_6291;
Myocarditis is a rare complication of MG but is more common with older age at diagnosis, thymoma, and anti-striated muscle antibodies which appear to be particularly important in the pathogenesis of this condition. Empiric early multimodal immunosuppression regimens including high dose steroids and azathioprine may be considered in this setting however randomized data is needed to determine the true impact of this strategy.
- |||||||||| Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
MYASTHENIA GRAVIS AND TAKOTSUBO SYNDROME (eAbstract site) - Jan 28, 2022 - Abstract #ACC2022ACC_2921; In patients with MG, Takotsubo syndrome has to be seen as a plausible and probable cause of chest pain, even if the patient is at rest and with no emotional distress, as in the classical presentation. The treatment strategy also has to be individualized, with ivabradine being a good alternative for betablockers.
- |||||||||| Raised ✋🏻: curiously after frequent TIAs,“ischemic event”,“I think it is subarachnoid hemorrhage”,“maybe it is Chiari”, “maybe hemiplegic migraine”, “PRES on CT scan, don’t know why”, IVIG, given for Myasthenia Gravis stopped them, but those episodes are not features of MG 1/2 (Twitter) - Jan 27, 2022
- |||||||||| Journal: High mobility group box 1 is involved in the pathogenesis of passive transfer myasthenia gravis model. (Pubmed Central) - Jan 27, 2022
As a result, serum HMGB1 levels tended to be higher and the quantitative score of muscle pathology showed greater HMGB1 deposition (P = 0.02) along with sparser AChR staining and more severe inflammation in the passive transfer MG rats (n = 6) than those in control rats (n = 6). These findings indicate that HMGB1 is an important mediator and biomarker for inflammation in the pathogenesis of MG and can be a therapeutic target in MG.
- |||||||||| Journal: Emerging drugs for the treatment of Myasthenia Gravis. (Pubmed Central) - Jan 27, 2022
Despite several promising novel agents, existing data as to the timing of initiation and duration of treatment, long term safety profile and utility in certain patient subsets are limited and require further research. Despite these considerations, the future of MG treatment is transitioning from broad-spectrum IST towards precise, target-driven and personalised immunotherapy.
- |||||||||| Tai'ai (telitacicept) / Rongchang Pharma
Review, Journal: Telitacicept: First Approval. (Pubmed Central) - Jan 27, 2022 Clinical studies of telitacicept in several other indications, including IgA nephropathy, MS, myasthenia gravis, neuromyelitis optica spectrum disorders, RA and Sjögren's syndrome are underway in China. This article summarizes the milestones in the development of telitacicept leading to this first approval for SLE.
- |||||||||| Journal: Lambert-Eaton myasthenic syndrome (Pubmed Central) - Jan 26, 2022
The relationship between the DELTA-P score and the risk of small-cell lung carcinoma could not be replicated. Symptomatic treatment with pyridostigmine represents an effective therapeutic alternative.
- |||||||||| Retrospective data, Journal: Minimally invasive thymectomy for myasthenia gravis: a 7-year retrospective study. (Pubmed Central) - Jan 26, 2022
The modified subxiphoid approach was found to be superior to the bilateral approach in video-assisted thoracic surgery thymectomy in terms of the surgical outcomes and yielded similar neurological outcomes. Therefore, the modified subxiphoid approach is recommended as an alternative to the bilateral approach in the treatment of patients with MG and thymic masses.
- |||||||||| Clinical, Journal, Patient reported outcomes: Patient-Reported Outcomes for Ocular Myasthenia Gravis. (Pubmed Central) - Jan 21, 2022
We have presented a case with a successful outcome, which highlights the importance of screening for lymphoma and thymoma in new presentations of MG. No abstract available
- |||||||||| Enspryng (satralizumab) / Roche
Enrollment open: A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis (clinicaltrials.gov) - Jan 19, 2022 P3, N=240, Recruiting, Keywords Alzheimer disease, thymoma, neuroinflammation, central cholinergic effects, acetylcholine receptor antibody. Active, not recruiting --> Recruiting
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Journal: A Case of MuSK Myasthenia Gravis Presenting With Persistent Respiratory Insufficiency. (Pubmed Central) - Jan 18, 2022 However, her most treatment refractory and quality of life limiting symptom continues to be respiratory insufficiency. Further investigation to better characterize differential response to treatment in this subset of patients with MuSK MG may be needed.
- |||||||||| Clinical, Journal: Granulomatous Myositis Associated With Acetylcholine Receptor Antibodies Without Clinical Myasthenia. (Pubmed Central) - Jan 18, 2022
In addition, we include rarely reported neuromuscular ultrasound findings of granulomatous myositis in a patient without sarcoidosis. Inflammatory myopathy may precede development of myasthenia gravis in myasthenia gravis associated with concurrent inflammatory myopathy, and it is important to remain vigilant for symptoms suggestive of myasthenia gravis, especially in the presence of positive myasthenia-associated antibodies.
- |||||||||| Clinical, Journal: Myasthenia Gravis in a Child After Graft-versus-Host Disease. (Pubmed Central) - Jan 18, 2022
Inflammatory myopathy may precede development of myasthenia gravis in myasthenia gravis associated with concurrent inflammatory myopathy, and it is important to remain vigilant for symptoms suggestive of myasthenia gravis, especially in the presence of positive myasthenia-associated antibodies. No abstract available
|